{"id":"https://openalex.org/W46443151","doi":null,"title":"Dihydropyridine calcium antagonists and the trough: peak ratio: focus on adverse effects.","display_name":"Dihydropyridine calcium antagonists and the trough: peak ratio: focus on adverse effects.","publication_year":1994,"publication_date":"1994-11-01","ids":{"openalex":"https://openalex.org/W46443151","mag":"46443151","pmid":"https://pubmed.ncbi.nlm.nih.gov/7707160"},"language":"en","primary_location":{"id":"pmid:7707160","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/7707160","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of hypertension. Supplement : official journal of the International Society of Hypertension","raw_type":"Journal Article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5063504269","display_name":"Martin G. Myers","orcid":"https://orcid.org/0000-0003-0468-5417","observed_orcids":["https://orcid.org/0000-0003-0468-5417"]},"institutions":[{"id":"https://openalex.org/I4210167439","display_name":"Sunnybrook Hospital","ror":"https://ror.org/008kn1a71","country_code":"CA","type":"healthcare","lineage":["https://openalex.org/I1323843004","https://openalex.org/I4210167439"]}],"countries":["CA"],"is_corresponding":true,"raw_author_name":"M G Myers","raw_affiliation_strings":["Division of Cardiology, Sunnybrook Hospital, Toronto, Ontario, Canada"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Division of Cardiology, Sunnybrook Hospital, Toronto, Ontario, Canada","institution_ids":["https://openalex.org/I4210167439"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":["https://openalex.org/A5063504269"],"corresponding_institution_ids":["https://openalex.org/I4210167439"],"apc_list":null,"apc_paid":null,"fwci":2.4145,"has_fulltext":false,"cited_by_count":12,"citation_normalized_percentile":{"value":0.88459281,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":null,"biblio":{"volume":"12","issue":"8","first_page":"S73","last_page":"6; discussion S76"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10144","display_name":"Blood Pressure and Hypertension Studies","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/2705","display_name":"Cardiology and Cardiovascular Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10144","display_name":"Blood Pressure and Hypertension Studies","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/2705","display_name":"Cardiology and Cardiovascular Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10493","display_name":"Ion channel regulation and function","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10924","display_name":"Cardiovascular Health and Disease Prevention","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/2705","display_name":"Cardiology and Cardiovascular Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/dihydropyridine-calcium-antagonists","display_name":"dihydropyridine calcium antagonists","score":0.9419999718666077},{"id":"https://openalex.org/keywords/trough-to-peak-ratio","display_name":"trough-to-peak ratio","score":0.8740000128746033},{"id":"https://openalex.org/keywords/nifedipine","display_name":"nifedipine","score":0.8100000023841858},{"id":"https://openalex.org/keywords/amlodipine","display_name":"amlodipine","score":0.996999979019165},{"id":"https://openalex.org/keywords/antihypertensive-effect","display_name":"antihypertensive effect","score":0.7699999809265137},{"id":"https://openalex.org/keywords/baroreflex","display_name":"baroreflex","score":0.7260000109672546},{"id":"https://openalex.org/keywords/pharmacokinetics","display_name":"pharmacokinetics","score":0.7369999885559082},{"id":"https://openalex.org/keywords/pharmacodynamics","display_name":"pharmacodynamics","score":0.9290000200271606},{"id":"https://openalex.org/keywords/adverse-drug-reactions","display_name":"adverse drug reactions","score":0.5529999732971191},{"id":"https://openalex.org/keywords/patient-tolerability","display_name":"patient tolerability","score":0.7760000228881836}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.9255475997924805},{"id":"https://openalex.org/C2781212610","wikidata":"https://www.wikidata.org/wiki/Q39094","display_name":"Dihydropyridine","level":3,"score":0.6815823316574097},{"id":"https://openalex.org/C2779066535","wikidata":"https://www.wikidata.org/wiki/Q39111","display_name":"Nifedipine","level":3,"score":0.5694441795349121},{"id":"https://openalex.org/C79752029","wikidata":"https://www.wikidata.org/wiki/Q808732","display_name":"Baroreceptor","level":4,"score":0.5683781504631042},{"id":"https://openalex.org/C84393581","wikidata":"https://www.wikidata.org/wiki/Q82642","display_name":"Blood pressure","level":2,"score":0.5495098233222961},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.5416392087936401},{"id":"https://openalex.org/C42219234","wikidata":"https://www.wikidata.org/wiki/Q131130","display_name":"Anesthesia","level":1,"score":0.5400726199150085},{"id":"https://openalex.org/C120770815","wikidata":"https://www.wikidata.org/wiki/Q14859627","display_name":"Vasodilation","level":2,"score":0.4851563572883606},{"id":"https://openalex.org/C2778375690","wikidata":"https://www.wikidata.org/wiki/Q7814214","display_name":"Tolerability","level":3,"score":0.4446745216846466},{"id":"https://openalex.org/C2780648877","wikidata":"https://www.wikidata.org/wiki/Q420644","display_name":"Felodipine","level":3,"score":0.4102250337600708},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.30753427743911743},{"id":"https://openalex.org/C519063684","wikidata":"https://www.wikidata.org/wiki/Q706","display_name":"Calcium","level":2,"score":0.3001722991466522},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.2915263772010803},{"id":"https://openalex.org/C2777953023","wikidata":"https://www.wikidata.org/wiki/Q1073121","display_name":"Heart rate","level":3,"score":0.14912709593772888}],"mesh":[{"descriptor_ui":"D002121","descriptor_name":"Calcium Channel Blockers","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":true},{"descriptor_ui":"D002121","descriptor_name":"Calcium Channel Blockers","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":false},{"descriptor_ui":"D002121","descriptor_name":"Calcium Channel Blockers","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006973","descriptor_name":"Hypertension","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D009543","descriptor_name":"Nifedipine","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":true},{"descriptor_ui":"D009543","descriptor_name":"Nifedipine","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":false},{"descriptor_ui":"D009543","descriptor_name":"Nifedipine","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":false},{"descriptor_ui":"D014664","descriptor_name":"Vasodilation","qualifier_ui":"Q000187","qualifier_name":"drug effects","is_major_topic":true}],"locations_count":2,"locations":[{"id":"pmid:7707160","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/7707160","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of hypertension. Supplement : official journal of the International Society of Hypertension","raw_type":"Journal Article"},{"id":"mag:46443151","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/7707160","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":null,"is_accepted":false,"is_published":false,"raw_source_name":"PubMed","raw_type":null}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3","score":0.98580002784729}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2041668367","https://openalex.org/W2004773717","https://openalex.org/W6983575734","https://openalex.org/W62461058","https://openalex.org/W2103616575","https://openalex.org/W60128748","https://openalex.org/W52971044","https://openalex.org/W2039963240","https://openalex.org/W7097781595","https://openalex.org/W6999799644"],"abstract_inverted_index":{"EFFECTS":[0],"OF":[1,85],"SHORTER-ACTING":[2],"CALCIUM":[3],"ANTAGONISTS:":[4],"The":[5,88,148],"antihypertensive":[6,128],"effect":[7,129],"of":[8,143,158],"the":[9,17,36,59,131],"dihydropyridine":[10],"calcium":[11],"antagonists":[12],"is":[13,151],"highly":[14],"correlated":[15],"with":[16,72,137],"drug":[18],"plasma":[19],"concentration.":[20],"These":[21,62,113],"agents":[22,101],"reduce":[23],"blood":[24,45],"pressure":[25,46],"primarily":[26],"via":[27,58],"arteriolar":[28],"vasodilation.":[29],"More":[30],"rapidly":[31],"absorbed":[32],"formulations":[33,64],"such":[34,75,102],"as":[35,76,103],"nifedipine":[37,104],"capsule":[38],"quickly":[39],"produce":[40],"a":[41,51,116,126],"marked":[42],"fall":[43],"in":[44,54,141],"which":[47],"tends":[48],"to":[49,69],"provoke":[50],"reflex":[52,146],"increase":[53],"sympathetic":[55],"nervous":[56],"activity":[57],"baroreceptor":[60,145],"mechanism.":[61],"shorter-acting":[63],"are":[65,111,135],"therefore":[66],"more":[67,97],"likely":[68],"be":[70],"associated":[71,136],"vasodilatory":[73],"side-effects":[74],"flushing,":[77],"palpitations,":[78],"ankle":[79],"edema,":[80],"headaches":[81],"and":[82,93,109,123,154],"dizziness.":[83],"ADVANTAGES":[84],"LONGER-ACTING":[86],"AGENTS:":[87],"link":[89],"between":[90],"pharmacokinetics,":[91],"pharmacodynamics":[92],"side":[94,139],"effects":[95,140],"becomes":[96],"evident":[98],"when":[99],"longer-acting":[100],"gastrointestinal":[105],"therapeutic":[106],"system":[107],"(GITS)":[108],"amlodipine":[110],"examined.":[112],"drugs":[114],"have":[115],"trough:":[117],"peak":[118],"ratio":[119],"that":[120],"approaches":[121],"1,":[122],"thus":[124],"exert":[125],"uniform":[127],"over":[130],"dose":[132],"interval.":[133],"They":[134],"fewer":[138],"consequence":[142],"less":[144],"stimulation.":[147],"net":[149],"result":[150],"improved":[152],"efficacy":[153],"greater":[155],"patient":[156],"tolerability":[157],"these":[159],"compounds.":[160]},"counts_by_year":[],"updated_date":"2026-10-31T12:09:11.096373","created_date":"2016-06-24T00:00:00"}